OxFORD Asset Management LLP lifted its holdings in shares of Heska Corp (NASDAQ:HSKA) by 65.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,973 shares of the medical research company’s stock after purchasing an additional 17,333 shares during the period. OxFORD Asset Management LLP owned about 0.61% of Heska worth $3,878,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Royal Bank of Canada increased its stake in shares of Heska by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after purchasing an additional 499 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Heska in the 3rd quarter worth approximately $108,000. Victory Capital Management Inc. grew its stake in Heska by 17.5% in the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock worth $116,000 after acquiring an additional 169 shares during the period. State of Alaska Department of Revenue purchased a new stake in Heska in the 2nd quarter worth approximately $127,000. Finally, LS Investment Advisors LLC grew its stake in Heska by 411.2% in the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after acquiring an additional 1,028 shares during the period. 81.98% of the stock is owned by institutional investors and hedge funds.
Heska Corp (NASDAQ HSKA) opened at $81.98 on Friday. The firm has a market cap of $615.29, a price-to-earnings ratio of 44.47, a price-to-earnings-growth ratio of 2.27 and a beta of 0.75. Heska Corp has a 1-year low of $66.51 and a 1-year high of $115.00.
Several analysts have commented on HSKA shares. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a research note on Monday. B. Riley lowered their target price on shares of Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Canaccord Genuity started coverage on shares of Heska in a research note on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price for the company. Finally, BidaskClub cut shares of Heska from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $113.30.
In other Heska news, insider Michael J. Mcginley sold 7,826 shares of Heska stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 14.70% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/12/08/oxford-asset-management-llp-acquires-17333-shares-of-heska-corp-hska.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.